REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

26/09/2017 12:01

RNS Number : 8473R
AstraZeneca PLC
26 September 2017
26 September 2017 12:00 BST
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shares (ADSs) made under the AstraZeneca Restricted Share Plan (AZRSP) vested to Sean Bohen, a person discharging managerial responsibilities (PDMR) of the Company. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.
The AZRSP award was granted on 25 September 2015 and vested in two tranches on the first and second anniversaries of grant. Following the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Bohen became beneficially entitled to and received 12,385 ADSs.
For tax purposes, the fair market value of an ADS at vest was $33.95, being the closing price on the last trading day preceding the vesting day.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations


Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Christer Gruvris
Diabetes; Autoimmunity, Neuroscience & Infection
+44 203 749 5711
Nick Stone
Respiratory; Brilinta
+44 203 749 5716
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
1 
Details of the person discharging managerial responsibilities / person closely associated 
a)
Name 
Sean Bohen
2 
Reason for the notification 
a) 
Position/status 
Person discharging managerial responsibilities
b)
Initial notification /Amendment
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4i 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
b) 
Nature of the transaction 
Acquisition of ADSs pursuant to vesting under the AstraZeneca Restricted Share Plan, for nil consideration.
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
12,385
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
25 September 2017
f) 
Place of the transaction 
Outside a trading venue

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUNARRBNAKUAR